Core Insights - BostonGene has announced a strategic collaboration with Daiichi Sankyo to enhance antibody drug conjugate (ADC) development through AI-driven translational intelligence [1] Company Overview - BostonGene is recognized for developing a leading AI foundation model focused on tumor and immune biology [1] - Daiichi Sankyo is a prominent player in the pharmaceutical industry, specifically in the development of antibody drug conjugates [1] Collaboration Details - The collaboration aims to integrate advanced AI capabilities into Daiichi Sankyo's ADC development program [1] - The focus is on moving beyond traditional exploratory biomarker analysis to provide decision-ready insights for patient selection strategies [1]